#ResearchSpeak: treating PML in the context of persistent lymphopaenia

PML may not be an intractable problem; could immunotherapy be the solution? #ResearchSpeak #MSBlog

At present we don’t have an anti-viral agent that works against the JC virus that causes PML (progressive multifocal leukoencephalopathy). Therefore we have to rely on your own immune system to fight and clear the virus if you develop PML. This is why we wash out natalizumab with plasma exchange, or stop the immunosuppressive, when somebody develops PML. A problem arises when we can’t reconsititute CNS immunosurveillance or your immune system. The latter can happen with PIRTs (pulsed immune reconstitution treatments) or in people with persistent lymphopaenia. This is where immunotherapies are needed. 

One strategy is to give unfortunate people with PML in this situtation donor anti-JCV lymphocytes that are matched to their HLA (human leukocye antigens) to fight the infection. In short this is a immune transplant, i.e. giving them donor-matched T-lymphocytes to fight JCV. The study below presented at last year’s American Society of Haematology (ASH) meeting tested this approach in two patients. They used T-cells that were designed to attack BK virus that cross-reacts with JCV. In both these patients the approach worked. 

Logistics of this kind of therapy make it difficult. I advised lymphocyte donation a few year’s ago in patient with lupus with persistent lymphopaenia who had developed PML. By the time her team had mobilised an HLA-matched bone marrow donor who was JCV-positive the patient was in extremis and died before she could receive the donor lymphocytes. The logistics of immunotherapy for PML are not insignificant and ideally need to be established before hand so as not to delay treatment. In other words we need to screen potential lymphocyte donors beforehand so that we can call them in at short notice to harvest their lymphocytes. The other option is to rely on Pharma to create a bank of HLA-specific cytotoxic T-lymphocytes that are frozen and cane be mobilised within 24-48 hours as a licensed treatment for PML. The cost of the latter will probably be in the $100,000s compared to the former that will only cost £1,000s and can be bolted onto a bone marrow donation register. The latter can be funded by charities and former will need large investment from Pharma and regulatory approval. There is clearly an unmet need in the management and treatment of PML; we probably need to explore both approaches.

If I had more energy and time I would try and set this up. London would be a good place to do this as we have the largest bone marrow donor register in the UK and the highest population density in the UK. Any volunteers? 

Muftuoglu et al. Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy. ASH Session: 703. Adoptive Immunotherapy: Poster II. Sunday, December 4, 2016,

Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal demyelinating disorder of central nervous system caused by JC virus reactivation in patients with severe defects of cellular immunity. JC virus is genetically similar to BK virus. Both JC and BK virus express large tumor antigen (LT), small tumor antigen (ST), and the capsid proteins, VP1, VP2 and VP3 during replication. Due to antigenic epitope homology, ex vivo expanded BK virus specific T cells can also target JCV, especially for VP1 and LT. We developed a rapid, effective and GMP-compliant BK virus specific cytotoxic T lymphocyte (CTL) expansion method from peripheral blood mononuclear cells. Donor mononuclear cells were stimulated with a BK virus peptide mix in the presence of IL-2, IL-7 and IL-15 for 14 days. At the end of culture, the cells were harvested and cryopreserved until use.

Here, we report the first two cases of PML treated with BK virus specific CTL from the most closely HLA-matched donor.

Case 1. A 32-year-old female with a diagnosis of FLT3+ acute myeloid leukemia underwent double cord blood transplantation. Her post-transplant course was complicated by acute graft versus host disease involving skin and gastrointestinal tract, HHV-6 infection and BK virus related hemorrhagic cystitis. Twenty months after transplantation she presented with left-sided extremity weakness, slurred speech and mental confusion. The physical examination revealed ataxic gait and weakness of left lower extremity. MRI revealed abnormal pattern of parenchymal enhancement and signal abnormality in the posterior fossa, predominantly involving cerebellum and brain stem. Lumbar puncture revealed low levels of JC virus DNA (130 copies/ml). Repeat MRI three weeks later showed progression in the peduncle and right cerebellum with an increase in the CSF JC virus load to 700 copies/ml. At this point the patient received 105/kg BKV-specific CTLs expanded from a 3/6 HLA-matched allogeneic donor. There was no infusion-related toxicity. Two weeks later, there was a significant reduction in the JC virus titer to 78 copies/ml (limit of detection 72 copies/mL). HLA BW6+ donor CD4+ and CD8+ T-cells could be detected in the CSF 2 weeks after infusion, confirming that BK virus CTLs can home to inflammatory sites in the central nervous system. The lymphocytes in CSF showed a distinct phenotypic profile, mainly composed of recipient CD56bright NK cells and a mixture of donor and recipient CD4+ and CD8+ T cells. Donor T cells in CSF expressed very high levels of PD1 and CXCR3 compared to peripheral blood T-cells. Four weeks from the infusion, the neurological symptoms have resolved and repeat MRI confirmed near complete resolution of the lesions. The patient received a second CTL infusion 3 weeks after the first for persistent low positive JCV in the CSF. The patient remains essentially asymptomatic 4 months after BK virus specific CTL infusion with intermitted low positive JC virus DNA titers in the CSF. Donor T cells continue to be present in the CSF.

Case 2. A 73-year-old female with JAK2 positive myeloproliferative disorder on treatment with ruxolitinib for 8 years presented with altered mental state, blurred vision and unsteady gait. MRI revealed parieto-occipital subcortical signals in left hemisphere extending to the posterior temporal lobe suggestive of PML. JC virus load in the CSF was 230,000 copies/ml. She received a 2/6 HLA-matched allogeneic BK virus specific CTLs. Three weeks after infusion JC virus titer in the CSF decreased to 5,200 copies/ml and her condition stabilized. The MRI remained stable. Donor-derived CD4+ and CD8+ T cells were detected in the CSF, with high expression of PD1 and inflammatory chemokines on T cells. The patient received a second dose of BK virus specific CTL from the same donor one month after the first infusion. The CSF viral load reduced further to 800 copies/ml but the there was no clinical or radiological improvement, suggestive of irreversible CNS damage. The patient remains alive.

In this proof-of-principle study, we have used ex vivo expanded BK virus specific CTL to target PML, a disease without viable treatment strategies and with a universally fatal outcome. Both patients showed a remarkable reduction in the viral load and there was near complete resolution of symptoms and MRI findings in one case. Use of third party partially HLA-matched BK virus specific CTLs to treat PML holds promise.

CoI: multiple

2 thoughts on “#ResearchSpeak: treating PML in the context of persistent lymphopaenia”

  1. Why don't you ask the immunosuppressive community to fund this? Surely, this is something is everyone's interest. I am sure several pharmaceutical companies would be interested in this project?

  2. Why not an autologous transplant? If advanced planning is being discussed, bone marros "self-donation" appears reasonable before starting Natalizumab

Leave a Reply

%d bloggers like this: